Publications

2021 – Present

• Pahus MH, Zheng Y, Olefsky M, Gunst JD, Tebas P, Taiwo B, Søgaard OS, Peluso MJ, Lie Y, Reeves JD, Petropoulos CJ, Caskey M, Bar KJ. Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies. J Infect Dis. 2024 Oct 23:jiae486. 

• Richard J, Sannier G, Zhu L, Prévost J, Marchitto L, Benlarbi M, Beaudoin-Bussières G, Kim H, Sun Y, Chatterjee D, Medjahed H, Bourassa C, Delgado G-G, Dubé M, Kirchhoff F, Hahn BH, Kumar P, Kaufmann DE, Finzi A. CD4 downregulation precedes Env expression and protects HIV-1-infected cells from ADCC mediated by non-neutralizing antibodies. mBio. 2024 Oct 7:e0182724. 

• Coler B, Smith GH, Arora AK, Wells A, Solso S, Dullano C, Concha-Garcia S, Hill E, Riggs PK, Korolkova A, Deiss R, Smith D, Sundermann EE, Gianella S, Chaillon A, Dubé K. Quality of Life in People with HIV at the End of Life: Preliminary Results from the Last Gift Observational Cohort Study. J Acquir Immune Defic Syndr. 2024 Oct 3.

• Giron LB, Pasternak AO, Abdel-Mohsen M. Soluble markers of viral rebound and post-treatment HIV control. Curr Opin HIV AIDS. 2024 Sep 26. doi: 10.1097/COH.0000000000000889. Epub ahead of print. 

• Papasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S, Mounzer K, Kostman JR, Tebas P, Bar-Or A, Muthumani K, Montaner LJ. Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies. J Immunol. 2024 Sep 15;213(6):808-822.

• Dubé K, Villa TJ, Freshwater W, Mauk B, Rid A, Peluso MJ. Partner protections in HIV cure-related trials involving analytical treatment interruption: Updated toolkit to mitigate HIV transmission risk. J Virus Erad. 2024 Sep 11;10(3):100386. 

• Nkwelle CE, Stephens U, Liang K, Cassel J, Salvino JM, Montaner LJ, Ndip RN, Esemu SN, Ntie-Kang F, Tietjen I. A high-throughput, microplate reader-based method to monitor in vitro HIV latency reversal in the absence of flow cytometry. bioRxiv [Preprint]. 2024 Sep 11:2024.09.11.612557. 

• Dubé K, Perez-Brumer A, Patel H, Zhou C, Dee L, Graham G, Meanley S, Philbin MM. “This Is Actually a Really Unique Moment in Time”: Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions-A Qualitative Interview Study in the United States. AIDS Res Hum Retroviruses. 2024 Aug;40(8):455-463. 

• Lee MJ, Eason M, Castagna A, Laura G, De Scheerder MA, Riley J, Tebas P, Gunst J, Søgaard O, Florence E, Kroon E, De Souza M, Mothe B, Caskey M, Fidler S. The impact of analytical treatment interruptions and trial interventions on time to viral re-suppression in people living with HIV restarting ART in cure-related clinical studies: a systematic review and meta-analysis. J Int AIDS Soc. 2024 Aug;27(8):e26349. 

• Kroll KW, Hueber B, Balachandran H, Afifi A, Manickam C, Nettere D, Pollara J, Hudson A, Woolley G, Ndhlovu LC, Reeves RK. FcαRI (CD89) is upregulated on subsets of mucosal and circulating NK cells and regulates IgA-class specific signaling and functions. Mucosal Immunol. 2024 Aug;17(4):692-699. 

• Sugawara S, Lee E, Craemer MA, Pruitt A, Balachandran H, Gressens SB, Kroll K, Manickam C, Li Y, Jost S, Woolley G, Reeves RK. Knockdowns of CD3zeta Chain in Primary NK Cells Illustrate Modulation of Antibody-Dependent Cellular Cytotoxicity Against Human Immunodeficiency Virus-1. AIDS Res Hum Retroviruses. 2024 Aug 8. doi: 10.1089/AID.2023.0114. Epub ahead of print.

• Armani-Tourret M, Bone B, Tan TS, Sun W, Bellefroid M, Struyve T, Louella M, Yu XG, Lichterfeld M. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat Rev Microbiol. 2024 Jun;22(6):328-344.

• Marchitto L, Richard J, Prévost J, Tauzin A, Yang D, Chiu T, Chen HC, Díaz-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussières G, Anand SP, Dionne K, Bélanger É, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB 3rd, Finzi A. The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity. bioRxiv [Preprint]. 2024 Jun 7:2024.06.07.597978. 

• Teixeira AR, Bittar C, Silva Santos GS, Oliveira TY, Huang AS, Linden N, Ferreira IATM, Murdza T, Muecksch F, Jones RB, Caskey M, Jankovic M, Nussenzweig MC. Transcription of HIV-1 at sites of intact latent provirus integration. bioRxiv [Preprint]. 2024 Apr 29:2024.04.26.591331. 

• Whitehill GD, Joy J, Marino FE, Krause RJ, Mallick S, Courtney HM, Park K, Carey JW, Hoh R, Hartig H, Pae V, Sarvadhavabhatla S, Donaire MSB, Deeks SG, Lynch RM, Lee SA, Bar KJ. Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1. J Clin Invest. 2024 Apr 23:e176673.

• Giron LB, Liu Q, Adeniji OS, Yin X, Kannan T, Ding J, Lu DY, Langan S, Zhang J, Azevedo JLLC, Li SH, Shalygin S, Azadi P, Hanna DB, Ofotokun I, Lazar J, Fischl MA, Haberlen S, Macatangay B, Adimora AA, Jamieson BD, Rinaldo C, Merenstein D, Roan NR, Kutsch O, Gange S, Wolinsky SM, Witt MD, Post WS, Kossenkov A, Landay AL, Frank I, Tien PC, Gross R, Brown TT, Abdel-Mohsen M. Immunoglobulin G N-glycan markers of accelerated biological aging during chronic HIV infection. Nat Commun. 2024 Apr 10;15(1):3035.

• Board NL, Yuan Z, Wu F, Moskovljevic M, Ravi M, Sengupta S, Mun SS, Simonetti FR, Lai J, Tebas P, Lynn K, Hoh R, Deeks SG, Siliciano JD, Montaner LJ, Siliciano RF. Bispecific antibodies promote natural killer cell-mediated elimination of HIV-1 reservoir cells. Nat Immunol. 2024 Mar;25(3):462-470.

• Kufera JT, Armstrong C, Wu F, Singhal A, Zhang H, Lai J, Wilkins HN, Simonetti FR, Siliciano JD, Siliciano RF. CD4+ T cells with latent HIV-1 have reduced proliferative responses to T cell receptor stimulation. J Exp Med. 2024 Mar 4;221(3):e20231511.

• Bone B, Lichterfeld M. “Block and lock” viral integration sites in persons with drug-free control of HIV-1 infection. Curr Opin HIV AIDS. 2024 Feb 29.

• Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E. The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers. J Clin Invest. 2024 Feb 20;134(8):e174215.

• Reeves DB, Rigau DN, Romero A, Zhang H, Simonetti FR, Varriale J, Hoh R, Zhang L, Smith KN, Montaner LJ, Rubin LH, Gange SJ, Roan NR, Tien PC, Margolick JB, Peluso MJ, Deeks SG, Schiffer JT, Siliciano JD, Siliciano RF, Antar AAR. Mild HIV-specific selective forces overlaying natural CD4+ T cell dynamics explain the clonality and decay dynamics of HIV reservoir cells. medRxiv [Preprint]. 2024 Feb 15:2024.02.13.24302704.

• Singh S, Giron LB, Shaikh MW, Shankaran S, Engen PA, Bogin ZR, Bambi SA, Goldman AR, Azevedo JLLC, Orgaz L, de Pedro N, González P, Giera M, Verhoeven A, Sánchez-López E, Pandrea I, Kannan T, Tanes CE, Bittinger K, Landay AL, Corley MJ, Keshavarzian A, Abdel-Mohsen M. Distinct intestinal microbial signatures linked to accelerated systemic and intestinal biological aging. Microbiome. 2024 Feb 22;12(1):31.

• Zhou Y, Jadlowsky J, Baiduc C, Klattenhoff AW, Chen Z, Bennett AD, Pumphrey NJ, Jakobsen BK, Riley JL. Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. PLoS Pathog. 2023 Dec 15;19(12):e1011853.

• Docken SS, McCormick K, Pampena MB, Samer S, Lindemuth E, Pinkevych M, Viox EG, Wu Y, Schlub TE, Cromer D, Keele BF, Paiardini M, Betts MR, Bar KJ, Davenport MP. Preferential selection of viral escape mutants by CD8+ T cell ‘sieving’ of SIV reactivation from latency. PLoS Pathog. 2023 Nov 30;19(11):e1011755

• Armani-Tourret M, Gao C, Hartana CA, Sun W, Carrere L, Vela L, Hochroth A, Bellefroid M, Sbrolla A, Shea K, Flynn T, Roseto I, Rassadkina Y, Lee C, Giguel F, Malhotra R, Bushman FD, Gandhi RT, Yu XG, Kuritzkes DR, Lichterfeld M. Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a. Cell. 2024 Feb 29;187(5):1238-1254.e14.

• Dubé K, Perez-Brumer A, Patel H, Zhou C, Dee L, Graham G, Meanley S, Philbin M. “This is actually a really unique moment in time”: Navigating Long-Acting HIV Treatment and HIV Cure Research with Analytical Treatment Interruptions – A Qualitative Interview Study in the United States. AIDS Res Hum Retroviruses. 2024 Feb 22. doi: 10.1089/AID.2023.0105.

• Jost S, Lucar O, Lee E, Yoder T, Kroll K, Sugawara S, Smith S, Jones R, Tweet G, Werner A, Tomezsko PJ, Dugan HL, Ghofrani J, Rascle P, Altfeld M, Müller-Trutwin M, Goepfert P, Reeves RK. Antigen-specific memory NK cell responses against HIV and influenza use the NKG2/HLA-E axis. Sci Immunol. 2023 Dec 8;8(90):eadi3974.

• Wei Y, Davenport TC, Collora JA, Ma HK, Pinto-Santini D, Lama J, Alfaro R, Duerr A, Ho YC. Single-cell epigenetic, transcriptional, and protein profiling of latent and active HIV-1 reservoir revealed that IKZF3 promotes HIV-1 persistence. Immunity. 2023 Nov 14;56(11):2584-2601.e7.

• Sun W, Rassadkina Y, Gao C, Collens SI, Lian X, Solomon IH, Mukerji SS, Yu XG, Lichterfeld M. Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy. Elife. 2023 Nov 8;12:RP89837.

• Kreider EF, Ortega-Burgos Y, Dumeng-Rodriguez J, Gesualdi J, O’Brien C, Bracy D, Johnson J, Bowman J, Metzger D, Dine CJ, Favor K, Jordan-Sciutto KL, Momplaisir F. Early Engagement in HIV Research: Evaluation of the Penn CFAR Scholars Program Aimed at Increasing Diversity of the HIV/AIDS Workforce. J Acquir Immune Defic Syndr. 2023 Oct 1;94(2S):S28-S35.

• Wong M, Wei Y, Ho YC. Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels. Curr Opin HIV AIDS. 2023 Sep 1;18(5):246-256.

• Dubé K, Mthimkhulu D, Ngcobo W, Mindry D, Maphalala L, Pillay V, Tran W, Korolkova A, Ndung’u T, Dong K. ‘With this study, we have hope that something is coming’: community members’ perceptions of HIV cure-related research in Durban, South Africa – a qualitative focus group study. HIV Res Clin Pract. 2023 Jul 29;24(1):2243046.

• Collora JA, Ho YC. Integration site-dependent HIV-1 promoter activity shapes host chromatin conformation. Genome Res. 2023 Jun;33(6):891-906.

• Bone B, Lichterfeld M. Curating evidence for a cure of HIV-1 infection by hematopoietic stem cell transplantation. Med. 2023 May 12;4(5):285-287.

• Bone B, Lichterfeld M. “Block and lock” viral integration sites in persons with drug-free control of HIV-1 infection. Curr Opin HIV AIDS. 2024 Feb 29. doi: 10.1097/COH.0000000000000845. Epub ahead of print.

• Lancien M, Lichterfeld M. Proliferation of HIV-1 reservoir cells: The delusion of infinite growth. J Exp Med. 2024 Mar 4;221(3):e20232321.

• Armani-Tourret M, Bone B, Tan TS, Sun W, Bellefroid M, Struyve T, Louella M, Yu XG, Lichterfeld M. Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure. Nat Rev Microbiol. 2024 Feb 9. doi: 10.1038/s41579-024-01010-8.

• Hartana CA, Lancien M, Gao C, Rassadkina Y, Lichterfeld M, Yu XG. IL-15-dependent immune crosstalk between natural killer cells and dendritic cells in HIV-1 elite controllers. Cell Rep. 2023 Dec 26;42(12):113530.

• Dragoni F, Kwaa AK, Traut CC, Veenhuis RT, Woldemeskel BA, Camilo-Contreras A, Raymond HE, Dykema AG, Scully EP, Rosecrans AM, Smith KN, Bushman FD, Simonetti FR, Blankson JN. Proviral location affects cognate peptide-induced virus production and immune recognition of HIV-1 infected T cell clones. J Clin Invest. 2023 Nov 1;133(21):e171097

• Ndukwe SO, Patel H, Shelton B, Concha-Garcia S, Dullano C, Solso S, Hendrickx S, Riggs PK, Villa TJ, Kaytes A, Taylor J, Little SJ, Lessard D, Arora AK, Costiniuk CT, Eskaf S, Smith DM, Gianella S, Dubé K. People with HIV at the end of life and their next-of-kin/loved ones are willing to participate in interventional HIV cure-related research. AIDS. 2023 Oct 18. doi:  10.1097/QAD.0000000000003754.

• Kumar MR, Fray EJ, Bender AM, Zitzmann C, Ribeiro RM, Perelson AS, Barouch DH, Siliciano JD, Siliciano RF. Biphasic decay of intact SHIV genomes following initiation of antiretroviral therapy complicates analysis of interventions targeting the reservoir. Proc Natl Acad Sci U S A. 2023 Oct 24;120(43):e2313209120.

• Bilger A, Plenn E, Barg FK, Rendle KA, Carter WB, Lamour-Harrington A, Jones N, Peterson B, Sauceda JA, Tebas P, Mounzer K, Metzger D, Montaner LJ, Dubé K. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States. HIV Res Clin Pract. 2023 Oct 6;24(1):2267825.

• Goyal R, De Gruttola V, Gianella S, Caballero G, Porrachia M, Ignacio C, Woodworth B, Smith DM, Chaillon A. Identification of system-level features in HIV migration within a host. PLoS One. 2023 Sep 26;18(9):e0291367.

• Sugawara S, Hueber B, Woolley G, Terry K, Kroll K, Manickam C, Ram DR, Ndhlovu LC, Goepfert P, Jost S, Reeves RK. Multiplex interrogation of the NK cell signalome reveals global downregulation of CD16 signaling during lentivirus infection through an IL-18/ADAM17-dependent mechanism. PLoS Pathog. 2023 Sep 5;19(9):e1011629.

• McMyn NF, Varriale J, Fray EJ, Zitzmann C, MacLeod H, Lai J, Singhal A, Moskovljevic M, Garcia MA, Lopez BM, Hariharan V, Rhodehouse K, Lynn K, Tebas P, Mounzer K, Montaner LJ, Benko E, Kovacs C, Hoh R, Simonetti FR, Laird GM, Deeks SG, Ribeiro RM, Perelson AS, Siliciano RF, Siliciano JM. The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy. J Clin Invest. 2023 Sep 1;133(17):e171554.

• Marchitto L, Benlarbi M, Prévost J, Laumaea A, Descôteaux-Dinelle J, Medjahed H, Bourassa C, Gendron-Lepage G, Kirchhoff F, Sauter D, Hahn BH, Finzi A, Richard J. Impact of HIV-1 Vpu-mediated downregulation of CD48 on NK-cell-mediated antibody-dependent cellular cytotoxicity. mBio. 2023 Aug 31;14(4):e0078923.

• Marquis KA, Merenstein C, Bushman FD. 2-Hydroxyisovalerate Is Produced During Bacterial Vaginosis and Boosts HIV Infection in Resting T Cells. AIDS Res Hum Retroviruses. 2023 Aug 29. doi: 10.1089/AID.2022.0171.

• Sun W, Rassadkina Y, Gao C, Collens SI, Lian X, Solomon IH, Mukerji S, Yu XG, Lichterfeld M. Persistence of intact HIV-1 proviruses in the brain during antiretroviral therapy. bioRxiv [Preprint]. 2023 Aug 14:2023.06.26.546135. doi: 10.1101/2023.06.26.546135.

• Podgorski RM, Robinson JA, Smith MD, Mallick S, Zhao H, Veazey RS, Kolson DL, Bar KJ, Burdo TH. Transmitted/founder SHIV.D replicates in the brain, causes neuropathogenesis, and persists on combination antiretroviral therapy in rhesus macaques. Retrovirology. 2023 Aug 10;20(1):13.

• Giron LB, Liu Q, Adeniji OS, Yin X, Kannan T, Ding J, Lu DY, Langan S, Zhang J, Azevedo JLLC, Hanna DB, Ofotokun I, Lazar J, Fischl MA, Haberlen S, Macatangay B, Adimora AA, Jamieson BD, Rinaldo C, Merenstein D, Roan NR, Kutsch O, Gange S, Wolinsky S, Witt M, Post WS, Kossenkov A, Landay A, Frank I, Tien PC, Gross R, Brown TT, Abdel-Mohsen M. Plasma Glycomic Markers of Accelerated Biological Aging During Chronic HIV Infection. bioRxiv [Preprint]. 2023 Aug 10:2023.08.09.551369. doi: 10.1101/2023.08.09.551369.

• Dubé K, Barr E, Philbin M, Perez-Brumer A, Minalga B, Peterson B, Averitt D, Picou B, Martel K, Chung C, Mejía M, Cameron M, Graham G, Dee L, Dixon Diallo D, Gordon E, Korolkova A, Dyer T, Auerbach JD, Scully E, Dong KL, Gianella S. Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States. HIV Res Clin Pract. 2023 Aug 8;24(1):2246717.

• Geretz A, Ehrenberg PK, Clifford RJ, Laliberté A, Prelli Bozzo C, Eiser D, Kundu G, Yum LK, Apps R, Creegan M, Gunady M, Shangguan S, Sanders-Buell E, Sacdalan C, Phanuphak N, Tovanabutra S, Russell RM, Bibollet-Ruche F, Robb ML, Michael NL, Ake JA, Vasan S, Hsu DC, Hahn BH, Kirchhoff F, Thomas R. Single-cell transcriptomics identifies prothymosin α restriction of HIV-1 in vivo. Sci Transl Med. 2023 Aug 2;15(707):eadg0873.

• Buggert M, Price DA, Mackay LK, Betts MR. Human circulating and tissue-resident memory CD8 +  T cells. Nat Immunol. 2023 Jul;24(7):1076-1086.

• Patel H, Dubé K. To prescreen or not to prescreen for broadly neutralizing antibody sensitivity in HIV cure-related trials. J Virus Erad. 2023 Jul 18;9(3):100339.

• Bauer A, Lindemuth E, Marino FE, Krause R, Joy J, Docken SS, Mallick S, McCormick K, Holt C, Georgiev I, Felber B, Keele BF, Veazey R, Davenport MP, Li H, Shaw GM, Bar KJ. Adaptation of a transmitted/founder simian-human immunodeficiency virus for enhanced replication in rhesus macaques. PLoS Pathog. 2023 Jul 3;19(7):e1011059.

• Lynch RM, Bar KJ. Development of screening assays for use of broadly neutralizing antibodies in people with HIV. Curr Opin HIV AIDS. 2023 Jul 1;18(4):171-177.

• Tebas P, Lynn K, Azzoni L, Cocchella G, Papasavvas E, Fair M, Karanam B, Sharma P, Reeves JD, Petropoulos CJ, Lalley-Chareczko L, Kostman JR, Short W, Mounzer K, Montaner LJ. Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. AIDS. 2023 Jul 1; 37(8):p 1203-1207.

• Campbell CK, Dubé K, Sauceda JA, Sevelius JM, Green-Ajufo B, Brown B, Ndukwe S, Saberi P. Cash Transfer Apps are a Feasible, Acceptable, and More Equitable Method for Compensating Participants in HIV Research. J Acquir Immune Defic Syndr. 2023 Jul 1;93(3):e9-e11.

• Joshi LR, Gálvez NMS, Ghosh S, Weiner DB, Balazs AB. Delivery platforms for broadly neutralizing antibodies. Curr Opin HIV AIDS. 2023 Jul 1;18(4):191-208.

• Sanders-Beer BE, Archin NM, Brumme ZL, Busch M, Deleage C, O’Doherty U, Hughes SH, Jerome K, Jones RB, Karn J, Kearney MF, Keele B, Kulpa D, Laird G, Li JZ, Lichterfeld M, Nussenzweig MC, Persaud D, Yukl S, Siliciano RF, Mellors JW. Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. AIDS Res Hum Retroviruses. 2023 Jun 19. Doi: 10.1089/AID.2022.00188.

• Dubé K, Peterson B, Jones NL, Onorato A, Carter WB, Dannaway C, Johnson S, Hayes R, Hill M, Maddox R, Riley JL, Shull J, Metzger D, Montaner LJ. Community engagement group model in basic and biomedical research: lessons learned from the BEAT-HIV Delaney Collaboratory towards an HIV-1 cure. Res Involv Engagem. 2023 Jun 8;9(1):39.

• Marquis KA, Everett J, Cantu A, McFarland A, Sherrill-Mix S, Krystal M, Parcella K, Gillis E, Fridell RA, Bushman FD. The HIV-1 Capsid-Targeted Inhibitor GSK878 Alters Selection of Target Sites for HIV DNA Integration. AIDS Res Hum Retroviruses. 2023 Jun 7. Doi: 10.1089/AID.2022.0161. Online ahead of print.

• Dubé K, Morton T, Fox L, Dee L, Palm D, Villa TJ, Freshwater W, Taylor J, Graham G, Carter WB, Sauceda JA, Peluso MJ, Rid A. A partner protection package for HIV cure-related trials involving analytical treatment interruptions. Lancet Infect Dis. 2023 Jun 6:S1473-3099(23)00267-0.

• Dubé K, Shelton B, Patel H, Ndukwe SO, Concha-Garcia S, Dullano C, Solso S, Hendrickx S, Kaytes A, Taylor J, Villa TJ, Little SJ, Riggs PK, Lessard D, Arora AK, Costiniuk CT, Eskaf S, Smith DM, Gianella S. Perceived risks and benefits of enrolling people with HIV at the end of life in cure research in Southern California, United States. J Virus Erad. 2023 Jun 5;9(2):100328. doi: 10.1016/j.jve.2023.100328. PMID: 37440872; PMCID: PMC10334343.

• Dubé K, Villa TJ, Taylor J, Kaytes A, Moore DJ, Little SJ, Chaillon A, Smith DM, Gianella S. A Community-Driven Framework to Prioritize the Use of Donated Human Biological Materials in the Context of HIV Cure-Related Research at the End of Life. Pathog Immun. 2023 May 24;8(1):1-16.

• Tietjen I, Schonhofer C, Sciorillo A, Naidu ME, Haq Z, Kannan T, Kossenkov AV, Rivera-Ortiz J, Mounzer K, Hart C, Gyampoh K, Yuan Z, Beattie KD, Rali T, Shuda McGuire K, Davis RA, Montaner LJ. The Natural Stilbenoid (-)-Hopeaphenol Inhibits HIV Transcription by Targeting Both PKC and NF-κB Signaling and Cyclin-Dependent Kinase 9. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0160022.

• White JA, Wu F, Yasin S, Moskovljevic M, Varriale J, Dragoni F, Camilo Contreras A, Duan J, Zheng MY, Tadzong NF, Patel HB, Quiambao JMC, Rhodehouse K, Zhang H, Lai J, Beg SA, Delannoy M, Kilcrease C, Hoffmann CJ, Poulin S, Chano F, Tremblay C, Cherian J, Barditch-Crovo P, Chida N, Moore RD, Summers MF, Siliciano RF, Siliciano JD, Simonetti FR. Clonally expanded HIV-1 proviruses with 5′-Leader defects can give rise to nonsuppressible residual viremia. J Clin Invest. 2023 March 15. 133(6):e165245.

• Yuan Z, Giron L, Hart C, Gyampoh A, Koshy J, Hong KY, Niki T, Premeaux TA, Ndhlovu LC, Montaner LJ*, Abdel-Mohsen M.* Human galectin-9 promotes the expansion of HIV reservoirs in vivo in humanized mice. AIDS. 2023 Mar 15. 37(4): 571-577.

• Wu VH, Nguyen S, Nordin JML, Joy J, Mampe F, Tebas P, Montaner L.J, Bar KJ, Vella LA, Betts MR. Profound phenotypic and epigenetic heterogeneity of the HIV-1 infected CD4+ T cell reservoir. Nature Immunology. 2023 Feb. 24(2): 359-370.

• Thobakgale C, Jost S. Editorial: Innate immune responses in HIV controllers. Front Immunol. 2023 Feb 15;14:1159278.

• Sun W, Gao C, Hartana CA, Osborn MR, Einkauf KB, Lian X, Bone B, Bonheur N, Chun TW, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature. 2023 Feb. 614(7947): 309-317.

• Woolley G, Mosher M, Kroll K, Jones R, Hueber B, Sugawara S, Manickam C, Terry K, Varner V, Lifton M, Ram D, Fennessey CM, Keele BF, Reeves RK. Natural Killer Cells Regulate Acute SIV Replication, Dissemination, and Inflammation, but Do Not Impact Independent Transmission Events. J Virol. 2023 Jan 31;97(1):e0151922.

• Lian X, Seiger KW, Parsons EM, Gao C, Sun W, Gladkov GT, Roseto IC, Einkauf KB, Osborn MR, Chevalier JM, Jiang C, Blackmer J, Carrington M, Rosenberg ES, Lederman MM, McMahon DK, Bosch RJ, Jacobson JM, Gandhi RT, Peluso MJ, Chun TW, Deeks SG, Yu XG, Lichterfeld M. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe. 2023 Jan 11;31(1):83-96.e5.

• Laumaea A, Marchitto L, Ding S, Beaudoin-Bussières G, Prévost J, Gasser R, Chatterjee D, Gendron-Lepage G, Medjahed H, Chen HC, Smith AB 3rd, Ding H, Kappes JC, Hahn BH, Kirchhoff F, Richard J, Duerr R, Finzi A. Small CD4 mimetics sensitize HIV-1-infected macrophages to antibody-dependent cellular cytotoxicity. Cell Rep. 2023 Jan 10;42(1):111983.

• Wei Y, Ho Y-C. Interferon opens up: HIV-induced inflammation reconfigures 3D chromatin conformation and affects where HIV integrates. Mol Cell. 2022 Dec 15;82(24):4585-4587.

• Campbell DM, Cowlings PD, Tholanah M, Robinson MJ, Graham G, Aseru S, Dubé K, Cohn SE, Bar KJ, Connick E, Mngqbisa R, Scully EP, Stockman JK, Gianella S. A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research. J Acquir Immune Defic Syndr. 2022 Dec 15;91(5):e12-e14.

• Saini P, Adeniji OS, Abdel-Mohsen M. Inhibitory Siglec-sialic acid interactions in balancing immunological activation and tolerance during viral infections. EBioMedicine. 2022 Dec; 86:104354.

• Dubé K, Kanazawa J, Roebuck C, Johnson S, Carter WB, Dee L, Peterson B, Lynn KM, Lalley-Chareczko L, Hiserodt E, Kim S, Rosenbloom D, Evans BR, Anderson M, Hazuda DJ, Shipley L, Bateman K, Howell BJ, Mounzer K, Tebas P, Montaner LJ. “We are looking at the future right now”: Community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States. HIV Research & Clinical Practice. 2022 December. 23(1): 120-135.

• Riggs PK, Chaillon A, Jiang G, Letendre SL, Tang Y, Taylor J, Kaytes A, Smith DM, Dubé K, Gianella S. Lessons for Understanding Central Nervous System HIV Reservoirs from the Last Gift Program. Curr HIV/AIDS Rep. 2022 Dec;19(6):566-579.

• Dubé K, Campbell CK, Eskaf S, Sauceda JA, Ndukwe S, Henley L, Persaud D, Deeks SG, Auerbach JD, Saberi P. Willingness of Racially Diverse Young Adults Living with HIV to Participate in HIV Cure Research: A Cross-Sectional Survey in the United States. AIDS Res Hum Retroviruses. 2022 Nov 10. Doi: 10.1089/AID.2022.0005.

• Anikeeva N, Steblyanko M, Kuri-Cervantes L, Buggert M, Betts MR, Sykulev Y. The immune synapses reveal aberrant functions of CD8 T cells during chronic HIV infection. Nat Commun. 2022 Oct 28;13(1):6436.

• Dai W, Wu F, McMyn N, Song B, Walker-Sperling VE, Varriale J, Zhang H, Barouch DH, Siliciano JD, Li W, Siliciano RF. Genome-wide CRISPR screens identify combinations of candidate latency reversing agents for targeting the latent HIV-1 reservoir. Sci Transl Med. 2022 Oct 19;14(667):eabh3351.

• Neergaard R, Jones N, Roebuck C, Rendle KA, Barbati Z, Peterson B, Tebas P, Mounzer KC, Metzger DS, Montaner LJ. “I know that I was a part of making a difference”: Participant motivations for joining a cure-directed HIV trial with an analytical treatment interruption. AIDS Research and Human Retroviruses. 2022 Sept 15. Doi: 10/1089/AID.2022.0040. Online ahead of print.

• Dubé K, Agarwal H, Stockman JK, Auerbach JD, Sauceda JA, Conroy AA, Johnson MO. “I Would Absolutely Need to Know That My Partner Is Still Going to be Protected”: Perceptions of HIV Cure-Related Research Among Diverse HIV Serodifferent Couples in the United States. AIDS Res Hum Retroviruses. 2022 Sep 8. Doi: 10.1089/AID.2022.0036. Online ahead of print.

• Addison MM, Ellis GI, Leslie GJ, Zawadzky NB, Riley JL, Hoxie JA, Eisenlohr LC. HIV-1-Infected CD4+ T Cells Present MHC Class II-Restricted Epitope via Endogenous Processing. J Immunol. 2022 Sep 1;209(5):864-873.

• Jost S. Holding back: HLA-associated inhibition of NK cells gives HIV a leg up. Cell Host Microbe. 2022 Aug 10;30(8):1072-1073.

• Dubé K, Agarwal H, Carter WB, Dee L, Taylor J, Roebuck C, Peterson B, Patel H, Ndukwe S, Lynn KM, Lalley-Chareczko L, Hiserodt E, Kim S, Rosenbloom D, Evans BR, Anderson M, Hazuda DJ, Bateman K, Howell BJ, Azzoni L, Mounzer K, Tebas P, Montaner LJ. Participant experiences using novel home-based blood collection device for viral load testing in the context of HIV cure trials with analytical treatment interruptions. HIV Research & Clinical Practice. 2022 Aug 2. 23(1):76-90.

• Lichterfeld M, Gao C, Yu XG. An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection. Trends Immunol. 2022 Aug;43(8):608-616.

• Pedersen SF, Collora JA, Kim RN, Yang K, Razmi A, Catalano AA, Yeh YJ, Mounzer K, Tebas P, Montaner LJ, Ho YC. Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen. J Virol. 2022 Jul 13;96(13):e0057722.

• Campbell DM, Dubé K, Cowlings PD, Dionicio P, Tam RM, Agarwal H, Stockman JK, Auerbach JD, Sauceda JA, Conroy AA, Johnson MO. “It comes altogether as one:” perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States. BMC Public Health. 2022 Jul 9;22(1):1317.

• Tembeni B, Sciorillo A, Invernizzi L, Klimkait T, Urda L, Moyo P, Naidoo-Maharaj D, Levitties N, Gyampoh K, Zu G, Yuan Z, Mounzer K, Nkabinde S, Nkabinde M, Gqaleni N, Tietjen I, Montaner LJ, Maharaj V. HPLC-Based Purification and Isolation of Potent Anti-HIV and Latency Reversing Daphnane Diterpenes from the Medicinal Plant Gnidia sericocephala (Thymelaeaceae). Viruses. 2022 Jun 30;14(7):1437.

• Collora JA, Liu R, Pinto-Santini D, Ravindra N, Ganoza C, Lama JR, Alfaro R, Chiarella J, Spudich S, Mounzer K, Tebas P, Montaner LJ, van Dijk D, Duerr A, Ho YC. Single-cell multiomics reveals persistence of HIV-1 in expanded cytotoxic T cell clones. Immunity. 2022 June 14. 55(6): 1013-1031.e.7.

• Dubé K, Eskaf S, Barr L, Palm D, Hogg E, Simoni J, Sugarman J, Brown B, Sauceda JA, Henley L, Deeks SG, Fox L, Gandhi R, Smith DM, Li J. Participant Perspectives and Experiences Following an Intensively Monitored Antiretroviral Pause (IMAP) in the United States: Results from the AIDS Clinical Trials Group (ACTG) A5345 Biomarker Study. AIDS Res Hum Retroviruses. 2022 June. 38(6): 510-517.

• Giron LB, Abdel-Mohsen M. Curr HIV/AIDS Rep. Viral and Host Biomarkers of HIV Remission Post Treatment Interruption. 2022 Jun;19(3):217-233.

• Kreider EF, Bar KJ. HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies. Curr HIV/AIDS Rep. 2022 Jun;19(3):194-206.

• Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, Turroja M, Butler A, Ramos V, Seaman MS, Reeves JD, Petroupoulos CJ, Shimeliovich I, Gazumyan A, Jiang CS, Jilg N, Scheid JF, Gandhi R, Walker BD, Sneller MC, Fauci A, Chun TW, Caskey M, Nussenzweig MC. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022 Jun;606(7913):368-374.

• Wang M, Sciorillo A, Read S, Divsalar DN, Gyampoh K, Zu G, Yuan Z, Mounzer K, Williams DE, Montaner LJ, de Voogd N, Tietjen I, Andersen RJ. Ansellone J, a Potent in Vitro and ex Vivo HIV-1 Latency Reversal Agent Isolated from a Phorbas sp. Marine Sponge. J Nat Prod. 2022 May 27;85(5):1274-1281.

• Sugawara S, Reeves RK, Jost S. Learning to Be Elite: Lessons From HIV-1 Controllers and Animal Models on Trained Innate Immunity and Virus Suppression. Front Immunol. 2022;13:858383.

• Dubé K, Kanazawa J, Patel H, Louella M, Sylla L, Sheehy J, Dee L, Taylor J, Adair J, Anthony-Gonda K, Dropulić B, Sauceda JA, Peluso MJ, Deeks SG, Simoni J. Ethical and practical considerations for cell and gene therapy toward an HIV cure: findings from a qualitative in-depth interview study in the United States. BMC Med Ethics. 2022 Apr 9;23(1):39

• Prévost J, Richard J, Gasser R, Medjahed H, Kirchhoff F, Hahn BH, Kappes JC, Ochsenbauer C, Duerr R, Finzi A. Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4+ T Cell. J Virol. 2022 Mar 23;96(6):e0192921.

• White JA, Simonetti FR, Beg S, McMyn NF, Dai W, Bachmann N, Lai J, Ford WC, Bunch C, Jones JL, Ribeiro RM, Perelson AS, Siliciano JD, Siliciano RF. Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. Proc Natl Acad Sci U S A. 2022 Feb 8;119(6): e2120326119.

• Dubé K, Eskaf S, Hastie E, Agarwal H, Henley L, Roebuck C, Carter WB, Dee L, Taylor J, Mapp D, Campbell DM, Villa TJ, Peterson B, Lynn KM, Lalley-Chareczko L, Hiserodt E, Kim S, Rosenbloom D, Evans BR, Anderson M, Hazuda DJ, Shipley L, Bateman K, Howell BJ, Mounzer K, Tebas P, Montaner LJ. Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States. J Pers Med. 2022 Feb 7;12(2): 231.

• Siliciano JD, Siliciano RF. In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure. Annu Rev Pathol. 2022 Jan 24;17:271-294.

• Collora JA, Ho YC. The loud minority: Transcriptionally active HIV-1-infected cells survive, proliferate, and persist. Cell. 2022 Jan 20;185(2):227-229.

• Einkauf KB, Osborn MR, Gao C, Sun W, Sun X, Lian X, Parsons EM, Gladkov GT, Seiger KW, Blackmer JE, Jiang C, Yukl SA, Rosenberg ES, Yu XG, Lichterfeld M. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell. 2022 Jan 20;185(2):266-282.e15.

• Kanazawa J, Gianella S, Concha-Garcia S, Taylor J, Kaytes A, Christensen C, Patel H, Ndukwe S, Rawlings SA, Hendrickx S, Little S, Brown B, Smith D, Dubé K. Ethical and practical considerations for HIV cure-related research at the end-of-life: a qualitative interview and focus group study in the United States. BMC Med Ethics. 2022 Jan 11;23(1):2.

• Turk G, Seiger K, Lian X, Sun W, Parsons EM, Gao C, Rassadkina Y, Polo ML, Czernikier A, Ghiglione Y, Vellicce A, Varriale J, Lai J, Yuki Y, Martin M, Rhodes A, Lewin SR, Walker BD, Carrington M, Siliciano R, Siliciano J, Lichterfeld M, Laufer N, Yu XG. A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Ann Intern Med. 2022 Jan;175(1):95-100.

• Dubé K, Kanazawa J, Campbell C, Boone CA, Maragh-Bass AC, Campbell DM, Agosto-Rosario M, Stockman JK, Diallo DD, Poteat T, Johnson M, Saberi P, Sauceda JA. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry. AIDS Res Hum Retroviruses. 2022 Jan;38(1):50-63.

• Adeniji OS, Giron LB, Abdel-Mohsen M. Examining the Impact of Galectin-9 on Latent HIV Transcription. Methods Mol Biol. 2022; 2442:463-474.

• Lian X, Gao C, Sun X, Jiang C, Einkauf KB, Seiger KW, Chevalier JM, Yuki Y, Martin M, Hoh R, Peluso MJ, Carrington M, Ruiz-Mateos E, Deeks SG, Rosenberg ES, Walker BD, Lichterfeld M, Yu XG. Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Sci Transl Med.2021 Dec 15;13(624):eabl4097.

• Huang AS, Ramos V, Oliveira TY, Gaebler C, Jankovic M, Nussenzweig MC, Cohn LB. Integration features of intact latent HIV-1 in CD4+ T cell clones contribute to viral persistence. J Exp Med. 2021 Dec 6;218(12): e20211427.

• Adeniji OS, Kuri-Cervantes L, Yu C, Xu Z, Ho M, Chew GM, Shikuma C, Tomescu C, George AF, Roan NR, Ndhlovu LC, Liu Q, Muthumani K, Weiner DB, Betts MR, Xiao H, Abdel-Mohsen M. Siglec-9 defines and restrains a natural killer subpopulation highly cytotoxic to HIV-infected cells. PLoS Pathog. 2021 Nov 11;17(11):e1010034.

• Prévost J, Medjahed H, Vézina D, Chen HC, Hahn BH, Smith AB 3rd, Finzi A. HIV-1 Envelope Glycoproteins Proteolytic Cleavage Protects Infected Cells from ADCC Mediated by Plasma from Infected Individuals. Viruses. 2021 Nov 6;13(11): 2236.

• Dubé K, Kanazawa J, Dee L, Taylor J, Sauceda JA, Gianella S, Smith D, Deeks SG, Peluso MJ. Considerations for designing and implementing combination HIV cure trials: findings from a qualitative in-depth interview study in the United States. AIDS Res Ther. 2021 Oct 18;18(1):75.

• Stone M, Rosenbloom DIS, Bacchetti P, Deng X, Dimapasoc M, Keating S, Bakkour S, Richman DD, Mellors JW, Deeks SG, Lai J, Beg S, Siliciano JD, Pagliuzza A, Chomont N, Lackman-Smith C, Ptak RG, Busch MP. Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. J Infect Dis. 2021 Oct 13;224(7):1209-1218.

• Papasavvas E, Azzoni L, Ross BN, Fair M, Howell BJ, Hazuda DJ, Mounzer K, Kostman JR, Tebas P, Montaner LJ. Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption. AIDS. 2021 Oct 1;35(12):2051-2054.

• Bosso M, Stürzel CM, Kmiec D, Badarinarayan SS, Braun E, Ito J, Sato K, Hahn BH, Sparrer KMJ, Sauter D, Kirchhoff F. An additional NF-κB site allows HIV-1 subtype C to evade restriction by nuclear PYHIN proteins. Cell Rep. 2021 Sep 21;36(12):109735